###begin article-title 0
Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 400 402 400 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 403 405 403 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
In peripheral airways, acetylcholine induces contraction via activation of muscarinic M2-and M3-receptor subtypes (M2R and M3R). Cholinergic hypersensitivity is associated with chronic obstructive pulmonary disease and asthma, and therefore the identification of muscarinic signaling pathways are of great therapeutic interest. A pathway that has been shown to be activated via MR and to increase [Ca2+]i includes the activation of sphingosine kinases (SPHK) and the generation of the bioactive sphingolipid sphingosine 1-phosphate (S1P). Whether the SPHK/S1P signaling pathway is integrated in the muscarinic control of peripheral airways is not known.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
To address this issue, we studied precision cut lung slices derived from FVB and M2R-KO and M3R-KO mice.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 477 478 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 550 551 550 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 619 620 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 627 628 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
In peripheral airways of FVB, wild-type, and MR-deficient mice, SPHK1 was mainly localized to smooth muscle. Muscarine induced a constriction in all investigated mouse strains which was reduced by inhibition of SPHK using D, L-threo-dihydrosphingosine (DHS) and N, N-dimethyl-sphingosine (DMS) but not by N-acetylsphingosine (N-AcS), a structurally related agent that does not affect SPHK function. The initial phase of constriction was nearly absent in peripheral airways of M3R-KO mice when SPHK was inhibited by DHS and DMS but was unaffected in M2R-KO mice. Quantitative RT-PCR revealed that the disruption of the M2R and M3R genes had no significant effect on the expression levels of the SPHK1-isoform in peripheral airways.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 203 204 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 105 111 <span type="species:ncbi:10090">murine</span>
These results demonstrate that the SPHK/S1P signaling pathway contributes to cholinergic constriction of murine peripheral airways. In addition, our data strongly suggest that SPHK is activated via the M2R. Given the important role of muscarinic mechanisms in pulmonary disease, these findings should be of considerable therapeutic relevance.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 282 285 282 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;5</sub>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 360 361 360 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 368 369 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 455 456 455 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 460 461 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 468 469 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 622 623 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 647 649 641 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 650 652 644 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">I </sub>
###xml 653 654 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 655 656 649 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 822 823 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
Acetylcholine (ACh), released from parasympathetic nerve fibres, leads to bronchoconstriction via stimulation of muscarinic acetylcholine receptors (MRs) and subsequent increase in intracellular calcium levels [Ca2+]i. The MR-family consists of five molecularly distinct subtypes (M1-5R) that are coupled to heterotrimeric G-proteins [1,2]. Activation of the M2R and M4R subtypes generally decreases intracellular cAMP levels, whereas stimulation of the M1R, M3R and M5R subtypes leads to the activation of phospholipase Cbeta (PLCbeta) with subsequent generation of the second messenger inositol 1, 4, 5-trisphosphate (IP3) and an increase in [Ca2+]I [1,2]. Asthmatic patients show hypersensitivity to MR agonists, and consequently antimuscarinic agents are commonly used in treatment of upper and lower airway diseases [3].
###end p 11
###begin p 12
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 104 106 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">I</sub>
###xml 191 194 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 327 329 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 330 332 330 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 755 758 755 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 953 955 953 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 956 958 956 958 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1034 1035 1034 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1042 1043 1042 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1096 1097 1096 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1098 1099 1098 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1339 1340 1339 1340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1347 1348 1347 1348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1478 1479 1477 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1480 1482 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1652 1654 1651 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 906 911 <span type="species:ncbi:9606">human</span>
###xml 1357 1361 <span type="species:ncbi:10090">mice</span>
Several studies suggest that the PLC-IP3-signalling pathway is not solely responsible for changes in [Ca2+]I. For example, activation of the cyclic ADP-ribose pathway abolishes ACh-induced Ca2+ oscillations in smooth muscle of porcine airways (White et al. 2003). Another alternative pathway that has been shown to increase [Ca2+]i involves the activation of sphingosine kinases (SPHK) and the subsequent generation of the bioactive sphingolipid sphingosine 1-phosphate (S1P) [4-6]. While S1P is well known as an important extracellular mediator of many biological pathways, including cell survival, angiogenesis and cell migration, recent studies indicate that S1P is also an intracellular second messenger which is coupled to changes in intracellular Ca2+ levels [4-6]. In the airways, S1P has been shown to stimulate airway smooth muscle proliferation and cytokine release [7]. When applied to cultured human tracheal myocytes, S1P also increases [Ca2+]i and evokes contractile responses [7,8]. Moreover, muscarinic activation of M2R-and M3R-transfected HEK293 cells stimulates S1P synthesis [4,5]. In the present study we therefore tested the hypothesis that activation of the SPHK/S1P signalling pathway may contribute to MR-dependent regulation of peripheral airway diameter. For all studies we used airways from wild-type (wt) and M2R and M3R mutant mice that were ~200 mum in diameter. It is well known that smaller airways are mainly responsible for airway resistance [9,10]. Moreover previous studies clearly demonstrated differences between larger and smaller airways concerning functional responses, receptor expression or ion conductance [11].
###end p 12
###begin p 13
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 3 9 <span type="species:ncbi:10090">murine</span>
In murine tissues, S1P is synthesized after activation of two SPHK isoforms, SPHK1 and SPHK2. SPHK1 is highly expressed in adult lung [12-14], whereas the SPHK2 isoform shows much lower expression in lung tissue [15]. SPHK2 contains a nuclear localization sequence and has recently been identified as a nuclear protein capable of inhibiting DNA synthesis, whereas SPHK1 is mainly localized in the cytosol [14,16]. In the present study we therefore focused exclusively on the expression and potential functional role of the SPHK1 isoform in MR-mediated airway constriction.
###end p 13
###begin p 14
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 490 493 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 548 550 548 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 563 566 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 679 680 679 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 687 688 687 688 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 815 816 815 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 823 824 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 957 958 957 958 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 965 966 965 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 985 986 985 986 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 993 994 993 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1045 1046 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1053 1054 1053 1054 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 152 158 <span type="species:ncbi:10090">murine</span>
###xml 177 183 <span type="species:ncbi:10090">murine</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
The expression of the SPHK1 isoform was investigated by means of quantitative RT-PCR and immunohistochemistry using precision cut lung slices (PCLS) of murine lungs [17]. Using murine PCLS we also measured the constriction of small intraparenchymal airways in response to MR activation. Coupling of MRs to SPHK-activation was investigated by blocking SPHK with D, L-threo-dihydrosphingosine (DHS) or N, N-dimethyl-sphingosine (DMS, [18]). Moreover, the role of MR-dependent intracellular Ca2+ release on airway diameter was studied by inhibiting Ca2+-influx by La3+ and SKF 96365. Recent evidence indicates that MR agonists induce bronchoconstriction by activating a mixture of M2R and M3R subtypes, present on smooth muscle cells of extra-and intraparenchymal airways [19,20]. To study the potential roles of the M2R and M3R subtypes in SPHK1-dependent peripheral airway responses, we therefore also carried out functional studies with PCLS prepared from M2R-and M3R-deficient mice (M2R-KO, M3R-KO) and their corresponding wild type controls (M2R-wt, M3R-wt) [21,22].
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Animals
###end title 16
###begin p 17
###xml 101 102 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 108 109 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 113 114 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 121 122 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 207 208 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 218 219 218 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 294 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 372 373 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
Lungs were taken from 8-12 wk old FVB mice (Harlan-Winkelmann, Borchen, Germany), mice deficient in M2R or M3R (M2R-KO, M3R-KO) and their corresponding wild-type strains (M2R-wt, M3R-wt). The generation of M2R-KO-and M3R-KO mice has been described previously [21,22]. The M2R-KO mice and the M2R-wt mice had the following genetic background: 129J1 (50%) x CF1 (50%). The M3R-KO mice and the corresponding wild-type mice had the following genetic background: 129SvEv (50%) x CF1 (50%). The animals were killed by cervical dislocation. The mice were kept under specific pathogen free conditions until the experiments.
###end p 17
###begin title 18
Quantitative RT-PCR
###end title 18
###begin p 19
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 131 132 131 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 139 140 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 151 152 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 576 577 575 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 689 690 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 865 867 857 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 977 978 960 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1637 1638 1593 1594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 957 962 <span type="species:ncbi:10090">mouse</span>
Real-time quantitative PCR (iCycler, Bio-Rad, Munchen, Germany) was used to quantify levels of SPHK1 mRNA in PCLS of FVB, M2R-KO, M3R-KO, M2R-wt, and M3R-wt mice. Lung slices were transferred into lysis buffer (Qiagen, Heiden, Germany) and homogenized using a mixer mill with a frequency of 300 Hz (Qiagen). Total RNA was isolated according to the protocol recommended by the manufacturer (Rneasy kit, Qiagen). Contaminating DNA was removed using DNase (1 U/mug total RNA, Gibco-BRL, Life Technologies, Karlsruhe, Germany) in the presence of 20 mM Tris-HCl (pH 8.4), 2 mM MgCl2, 50 mM KCl for 15 min at 25degreesC. Equal amounts of RNA were reverse transcribed in the presence of 3 mM MgCl2, 75 mM KCl, 50 mM Tris-HCl (pH 8.3), 10 mM dithiothreitol, 0.5 mM dNTPs (Gibco-BRL) and 25 mug oligo (dT) (MWG Biotech, Ebersberg, Germany), with 200 U of Superscript RNase H- Reverse transcriptase (Gibco-BRL) for 50 min at 42degreesC. Gene specific PCR primers for mouse SPHK1 and beta2-microglobulin (SPHK1, gi:22094104, fw TCCAGAAACCCCTGTGTAGC, rev GCTCCCTAGGGCCAGTAAAC product size 188 bp, beta2-microglobulin gi:12861272 fw ATGGGAAGCCGAACATACTG, rev CAGTCTCAGTGGGGGTGAAT, product size 176 bp) were designed using Primer Expresstrade mark software (Applied Biosystems, Foster City, USA). All PCR-reactions were prepared in triplicate from four to eight animals using a ready-to-use kit according to the manufacturers protocol (QuantiTecttrade mark SYBR Green PCR Kit, Qiagen). Primers specific for beta-microglobulin were used for standardisation. The data were normalised by subtracting the threshold cycle (CT) levels between SPHK1 and beta2-microglobulin. In each independent experiment qRT-PCR reactions were performed in triplicate.
###end p 19
###begin title 20
Double-labelling immunofluorescence
###end title 20
###begin p 21
###xml 325 327 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 543 549 <span type="species:ncbi:9793">donkey</span>
###xml 555 561 <span type="species:ncbi:9986">rabbit</span>
Slices (220 mum thick) prepared for videomorphometry were fixed for 20 min in ice-cold acetone and washed repeatedly in 0.1 M phosphate buffer. Sections were covered for 1 h with blocking medium (50 % normal porcine serum in PBS) followed by overnight incubation with an antiserum directed against the SPHK1 isoform (1:400, [23]) in combination with a monoclonal FITC-labelled anti-alpha-smooth muscle actin antibody (1:500, clone 1A4, Sigma, Deisenhofen, Germany). The sections were then washed in PBS and covered for 1 h with Cy3-conjugated donkey anti-rabbit Ig antiserum (1:3000, Dianova, Hamburg, Germany). After incubation with the secondary antibody, the slides were washed in PBS and coverslipped in carbonate-buffered glycerol at pH 8.6. Omission of primary antisera or preabsorption of the SPHK1a antiserum with the corresponding synthetic peptide (20-100 mug antigen/ml diluted antiserum) abolished immunolabelling. The slides were evaluated by sequential confocal laser scanning microscopy (TCPSP, Leica, Bensheim, Germany) using the appropriate laser for Cy3 (excitation 543 nm) and FITC (excitation 488 nm).
###end p 21
###begin title 22
Videomorphometry
###end title 22
###begin p 23
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 543 550 536 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">en bloc</italic>
###xml 1649 1652 1634 1637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 1538 1542 <span type="species:ncbi:10090">mice</span>
PCLS were prepared using a slightly modified version of the protocol described by Martin et al. [24]. Briefly, the mice were killed by cervical dislocation and the lungs were perfused via the right ventricle with 37degreesC Krebs-Ringer buffer containing heparin (1000 I.U.), penicillin/streptomycin (1 %) and sodium nitroprusside (0.075 muM). The airways were filled via the cannulated trachea with agarose (low melting point agarose, 1.6 % in Krebs-Ringer buffer, Sigma, Deisenhofen, Germany). Subsequently, the lungs and heart were removed en bloc, placed in ice-cold HEPES-Ringer buffer and cut in 200-250 mum thick slices using a vibratome (VT1000S, Leica). Subsequently, the precision cut lung slices (PCLS) were incubated in minimal essential medium (MEM) at 37degreesC for 4-7 h. Experiments were performed in a lung slice superfusion chamber (Hugo Sachs Elektronik, March, Germany) mounted on an inverted microscope (Leica). Images were recorded using a CCD-camera (Stemmer Imaging, Puchheim, Germany) and analyzed using the Optimas 6.5 image analysis software (Stemmer). The slices were fixed in the chamber with nylon strings that were connected to a platinum ring. Viable airways of about 200 mum in diameter were examined and incubated in the slide chamber for 5 min in HEPES-Ringer buffer until the first image was acquired. The area of the airway lumen at the beginning of the experiment was defined as 100 % and bronchoconstriction or dilatation were expressed as relative decrease or increase of this area. Data from FVB mice and wt-strains were used only from those experiments where the reduction of luminal area in response to 10-6 M muscarine reached at least 25 %. Muscarine, [propoxy]-ethyl-1H-imidazole] (SKF96365), lanthanum chloride and N-acetylspingosine (N-AcS) were purchased from Sigma. D, L-threo-dihydrosphingosine (DHS) and N,N-dimethyl-sphingosine (DMS) were purchased from Biomol (Hamburg, Germany).
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
Data are presented as means +/- standard error of the mean (SEM) of 5-10 slices obtained from five to nine animals. Matched pairs were evaluated by Wilcoxon's rank sum test. In the case of more than 2 non-matched groups, Mann-Whitney U-test for comparison between two groups was conducted only when statistically significant differences were reached by the global Kruskal-Wallis test that was performed first. Differences were considered as statistically significant when p < 0.05.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 359 360 359 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 367 368 367 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 393 394 393 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 404 405 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 487 488 487 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 198 204 <span type="species:ncbi:10090">murine</span>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
The goal of the present study was to determine the potential involvement of SPHK1 activation in the MR-mediated constriction of small peripheral airways. To be able to measure the diameter of small murine airways, we used videomicroscopy of viable precision-cut lung slices (PCLS; [24,20]). Specifically, we analyzed the effects of SPHK1 blockade in FVB and M2R and M3R single-knockout mice (M2R-KO and M3R-KO mice, respectively) as well as the corresponding wild-type control animals (M2R-wt and M3R-wt mice, respectively).
###end p 27
###begin title 28
qRT-PCR
###end title 28
###begin p 29
###xml 88 89 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 96 97 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 206 207 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 288 289 285 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 296 297 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 445 447 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 526 527 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 537 538 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 570 571 567 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 582 583 579 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 630 632 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 669 670 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
We used qRT-PCR analysis to quantitate and compare SPHK1-mRNA levels between FVB mice, M2R-and M3R-deficient mice (M2R-KO, M3R-KO), and the corresponding wt control mice (M2R-wt, M3R-wt). Expression of beta2-microglobulin served as an internal control. We found that inactivation of the M2R and M3R genes had no significant effect on the relative expression levels of SPHK1 compared to their corresponding wt controls (Mann-Whitney U-test, Fig. 1A). This analysis also showed that SPHK1 expression was significantly lower in M2R-wt and M2R-KO mice, as compared to FVB, M3R-wt, and M3R-KO-mice (p < 0.05, Mann-Whitney U-test, Fig. 1A), perhaps due to the fact that the M2R-KO/wt mice have a genetic background that is somewhat different from that of the other mice used (for details see "Materials and Methods").
###end p 29
###begin p 30
###xml 170 172 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
A) Quantitative RT-PCR analysis of SPHK1 expression in PCLS from different mouse strains. The relative expression of SPHK1-mRNA in relation to the house-keeping gene beta2 microglobulin is shown. Data are given as means +/- S.E.M. of four independent experiments each carried out in triplicate. B) Indirect immunofluorescence studies examining SPHK1 expression in PCLS of FVB-mice. Immunoreactivity for SPHK1 was present in the wall of larger (a) and smaller (b) airways and in the media of pulmonary vessels (arrows in a, b). Consecutive sections (c, d) showing that preabsorption of the SPHK1 antiserum abolished immunolabelling (Pre, d). Bars = 50 mum.
###end p 30
###begin title 31
Immunohistochemistry
###end title 31
###begin p 32
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 439 441 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 513 515 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 517 518 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 624 625 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 700 701 696 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 715 716 711 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 96 102 <span type="species:ncbi:10090">murine</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
We used single-and double-labeling immunohistochemistry to examine the distribution of SPHK1 in murine peripheral lung. Strong SPHK1-immunoreactivity was detected in the smooth muscle cells of intraparenchymal bronchi (Figs. 1B, 2) and pulmonary arteries (Fig. 1B) and veins as confirmed by double-staining of a marker of smooth muscle cells, alpha-smooth muscle actin. Preabsorption of the SPHK1 antiserum abolished immunolabelling (Fig. 1B). Immunoreactivity for SPHK1 was absent in bronchial epithelium (Figs. 1B, 2). SPHK1 showed a granular cytoplasmatic localisation but was also found in smooth muscle membranes (Fig. 2). The pattern of SPHK1 immunoreactivity was very similar in PCLS of FVB, M2R-KO/wt, and M3R-KO/wt mice..
###end p 32
###begin p 33
###xml 462 463 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 490 491 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Expression of SPHK1 in PCLS from different mouse strains studied via confocal laser scanning microscopy. Representative confocal laser scanning micrographs of double labeling immunohistochemistry demonstrates the restriction of SPHK1-immunoreactivity to smooth muscle cells, identified by immunoreactivity for the marker protein alpha-smooth muscle actin (alpha-sma). SPHK1a-immunoreactivity was present in peripheral airway smooth muscle of knock-out animals (M2R-KO, a-d) and wild-type (M2R-wt, e-h, FVB, i-l). Granular immunoreactivity could be detected in the cytoplasm and in the membrane of smooth muscle cells. Bars = 50 mum
###end p 33
###begin title 34
Videomorphometry
###end title 34
###begin p 35
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FVB mice </italic>
###xml 152 155 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 346 349 346 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 424 429 424 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, B</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A&#8211;D</xref>
###xml 460 463 460 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 487 490 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 494 498 494 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 615 616 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 661 664 661 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 683 685 683 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 688 692 688 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 755 758 755 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 784 785 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 810 813 810 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 891 893 891 893 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 896 900 896 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 942 943 942 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1000 1001 1000 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
FVB mice In PCLS preparations from FVB mice, the luminal area of peripheral bronchi rapidly decreased within the first 2 minutes after application of 10-6 M muscarine, followed by a sustained decrease in presence of the agonist (Tab. 1, Fig. 3). Application of the SPHK inhibitors DMS and DHS alone for ten minutes prior to coadministration of 10-6 M muscarine had no significant effect on bronchial luminal diameter (Figs. 3A, B, 5A-D). Coadministration of 10-6 M muscarine with DHS (10-4 M-10-10 M) significantly reduced both the initial and the sustained phase of the muscarine induced bronchoconstriction (Tab. 1, Fig. 3B). Similarly, coadministration of 10-6 M muscarine with 10-6-10-10 M DMS reduced both phases of the muscarine response. However 10-4 M DHS had no effect (Tab. 1). Coadministration of 10-6 M muscarine with the structurally related sphingolipid N-acetylsphingosine (10-6-10-10 M) which has no effect on SPHK1 function [5] did not alter the muscarine induced constriction (Tab. 1).
###end p 35
###begin p 36
###xml 491 494 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Effects of N-AcS, DHS and DMS on muscarine-induced reductions in luminal airway area in FVB mice. The number of experiments (lungs/slices), mean airway diameter in mum, and the luminal airway area determined 1 min (1) and 15 min (2) after stimulation with muscarine (Mus) and 1 min (3) and 15 min (4) after repeated stimulation with muscarine or after repeated stimulation with muscarine in combination with N-AcS, DHS or DMS are shown. In all experiments, the muscarine concentration was 10-6 M. Data are given as means +/- S.E.M. Matched pairs (1 vs. 3; 2 vs. 4) were evaluated by Wilcoxon's rank sum test. Differences were considered as statistically significant when p < 0.05 (n.s., not significant).
###end p 36
###begin p 37
###xml 144 147 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 316 319 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 920 923 918 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 974 977 972 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1009 1012 1007 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1058 1062 1056 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 1112 1115 1110 1113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1161 1165 1159 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
Muscarine-induced reductions in luminal area of peripheral bronchi from FVB mice. (A) Luminal area of peripheral bronchi after application of 10-6 M muscarine (Mus) as recorded by videomorphometry. Data (means +/- S.E.M) were expressed as % luminal area. Bronchi from FVB mice (4 slices from 6 lungs) responded to 10-6 M muscarine until wash out (Wash). Time points 1-4 were chosen as indicators for initial and sustained constriction. 1 = luminal airway area 1 min after muscarine application, 2 = luminal airway area 15 min after muscarine application, 3 = luminal airway area 1 min after repeated muscarine application, 4 = luminal airway area 15 min after repeated muscarine application. Effect of DHS (B) and DMS (C) on muscarine-mediated reductions in luminal area of peripheral bronchi from FVB mice. The luminal area of peripheral bronchi (expressed in %) was recorded by videomorphometry after application of 10-6 M muscarine (Mus) alone and after application of 10-6 M muscarine together with (B) 10-6 M DHS (diamonds, 7 slices from 4 lungs) and 10-10 M DHS (triangles, 8 slices from 4 lungs) or (C) 10-6 M DMS (diamonds, 9 slices from 7 lungs) and 10-10 M DMS (triangles, 6 slices from 4 lungs). Bronchoconstriction responses were significantly reduced in the presence of DHS and DMS. The inhibition was more pronounced following coadministration of DMS. Data are given as means +/- S.E.M.
###end p 37
###begin p 38
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 181 184 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 210 218 210 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A, E, G</xref>
###xml 238 241 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 252 255 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 268 271 268 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 274 277 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 405 413 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C, E, G</xref>
###xml 453 456 453 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 512 515 512 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
Inhibition of Ca2+ entry by La3+ (10-6 M) considerably reduced the initial and strongly inhibited the sustained constriction of peripheral airways following the administration of 10-6 M muscarine (Tab. 2, Fig. 4A, E, G). Combination of 10-8 M DHS or 10-8 M DMS with La3+ (10-6 M) almost completely abolished the initial and the sustained phase of the muscarine-dependent bronchoconstriction (Tab. 2, Fig. 4C, E, G). The combination of DHS or DMS with La3+ further significantly reduced both phases compared to La3+ alone (Wilcoxon's rank sum test p < 0.05)
###end p 38
###begin p 39
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 158 160 158 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 180 183 180 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 209 212 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 264 267 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 608 611 607 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 618 620 617 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+</sup>
###xml 687 690 686 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 798 801 797 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
Effects of SKF96365 and La3+ alone and in combination with DHS or DMS on the muscarine-induced reductions in luminal airway area in FVB mice Effects of the Ca2+-entry inhibitors La3+ (10-6 M) and SKF 96365 (10-5 M) alone and in combination with DHS or DMS (both 10-6 M) on the muscarine induced reduction in luminal airway area (expressed in %). The number of experiments (lungs/slices), mean airway diameter in mum, and the luminal airway area determined 1 min (1) and 15 min (2) after stimulation with muscarine and 1 min (3) and 15 min (4) and after stimulation with muscarine (Mus) in combination with La3+ (Mus/La3+) or SKF96365 (Mus/SKF), or after stimulation with muscarine and La3+ or SKF96365 in combination with DHS or DMS are shown. In all experiments, the muscarine concentration was 10-6 M. Data are given as means +/- S.E.M. Matched pairs (1 vs. 3; 2 vs. 4) were evaluated by Wilcoxon's rank sum test. Differences were considered as statistically significant when p < 0.05.
###end p 39
###begin p 40
###xml 227 230 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 274 277 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 314 317 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 321 324 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 370 373 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 406 409 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 413 416 413 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 438 441 438 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 481 484 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 518 521 518 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 851 854 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 917 920 915 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 928 931 926 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 939 942 937 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 981 984 979 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 1191 1194 1189 1192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 1232 1235 1230 1233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 1436 1439 1434 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
Effect of various treatments on muscarine-mediated reductions in luminal area of peripheral bronchi from FVB mice. The luminal area of peripheral bronchi (expressed in %) was recorded by videomorphometry after application of 10-6 M muscarine alone or after application of 10-6 M muscarine in the presence of (A) 10-6 M La3+ (7 slices from 4 lungs), (B) SKF 96365 (SKF 10-5 M, 9 slices from 4 lungs), (C) 10-6 M La3+ in combination with 10-6 M DHS (7 slices from 4 lungs), or (D) 10-5 M SKF 96365 in combination with 10-6 M DHS (8 slices from 4 lungs). Data are given as means +/- S.E.M.E-F) Summary of effects of various treatments on muscarine-mediated reductions in luminal area of peripheral bronchi from FVB mice. Luminal area (expressed in %) determined 1 min (initial contraction, E) and 15 min (sustained contraction, G) after application of 10-6 M muscarine alone or of muscarine in combination with either La3+ (both 10-6 M) or La3+ in combination with DHS or DMS (both 10-8 M). Luminal area (expressed in %) determined 1 min (initial contraction, F) and 15 min (sustained contraction, H) after application of muscarine alone or of muscarine in combination with either SKF 96365 (10-5 M) or SKF 96365 in combination with 10-8 M DHS or DMS. Asterisks indicate p < 0.05 for the comparison with application of muscarine alone (E-F). Daggers indicate p < 0.05 for the comparison with application of muscarine in combination with La3+ (E, G). Data are given as means +/- S.E.M.
###end p 40
###begin p 41
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 225 233 225 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B, F, H</xref>
###xml 263 266 263 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 276 279 276 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 290 293 290 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 391 396 391 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4F, H</xref>
Blockade of Ca2+-entry by SKF96365 (10-5 M), which inhibits G-protein activated and voltage gated Ca2+-channels, greatly reduced both the initial and the sustained phase of muscarine-induced bronchoconstriction (Tab. 3, Fig. 4B, F, H). Combination of SKF96365 (10-5 M) with 10-8 M DMS or 10-8 M DHS exerted no further reduction of luminal airway area (Wilcoxon's rank sum test, Tab. 2, Fig. 4F, H).
###end p 41
###begin p 42
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 2 15 2 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R-KO/wt mice </italic>
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 261 266 261 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
###xml 336 337 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 439 440 439 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 450 451 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 477 480 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 592 597 592 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
###xml 671 672 671 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 694 695 692 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 722 723 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 730 735 726 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
###xml 793 794 789 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 814 815 808 809 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 841 842 833 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 849 854 841 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
###xml 927 928 919 920 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 938 939 930 931 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
M2R-KO/wt mice Muscarine (10-6 M) stimulation of PCLS preparations from M2R-KO mice resulted in an initial constriction response that was followed by a slight relaxation (4-8 % relaxation of luminal airway area within 3-15 min, 28 slices/27 lungs, Tab. 3, Fig. 5A, B). In contrast, in PCLS preparations from the corresponding wt mice (M2R-wt), the initial bronchoconstriction was followed by a sustained constriction response. In PCLS of M2R-KO and M2R-wt mice, DHS and DMS (10-8 M each) significantly inhibited the initial and sustained phase of muscarine induced constriction (Tab. 3, Fig. 5A, B). The initial constriction was inhibited by about 54 % (luminal area of M2R-wt: 48 +/- 11.5 %; M2R-KO: 61.5 +/- 9.5 %, Tab. 3, Fig. 5A, B) and the sustained phase by about 50 % (luminal area of M2R-wt: 34 +/- 12 %; M2R-KO: 67.5 +/- 15 %, Tab. 3, Fig. 5A, B). The degree of inhibition of the initial phase was comparable between M2R-wt and M2R-KO mice.
###end p 42
###begin p 43
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 464 467 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 474 477 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 545 548 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
Effects of DHS and DMS on muscarine-induced reductions in luminal airway area in PCLS from M2 R-KO and theircorresponding wild-type mice. The number of experiments (lungs/slices), mean airway diameter in mum, and the muscarine-induced constriction in luminal airway area (expressed in %) determined after 1 min (1) and 15 min (2) after stimulation with muscarine and 1 min (3) and 15 min (4) after stimulation with muscarine in combination with DHS or DMS (both 10-6 M or 10-8 M) are shown. In all experiments, the muscarine concentration was 10-6 M. The initial phase (1 vs 3) and the sustained phase (2 vs 4) of constriction were reduced in the presence of DHS or DMS. Data are given as means +/- S.E.M.
###end p 43
###begin p 44
###xml 372 375 372 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 473 476 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 509 510 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 521 522 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 561 564 561 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 581 582 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 668 669 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 824 825 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 831 832 830 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 891 892 890 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 914 915 913 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 982 985 981 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1046 1049 1045 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1099 1102 1098 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 1202 1203 1201 1202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1213 1214 1212 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1290 1291 1289 1290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1313 1314 1312 1313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1366 1369 1365 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1424 1427 1423 1426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1477 1480 1476 1479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 1580 1581 1579 1580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1591 1592 1590 1591 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 775 781 <span type="species:ncbi:10090">murine</span>
###xml 920 924 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
###xml 1329 1333 <span type="species:ncbi:10090">mice</span>
###xml 1597 1601 <span type="species:ncbi:10090">mice</span>
Muscarine-mediated changes in luminal area of peripheral bronchi from wild-type and MR deficient mice. Changes in luminal area of mouse peripheral airways were recorded by videomorphometry after cumulative application of different concentrations of muscarine. (A) Videomorphometric images of precision cut lung slices before (), 1 min after stimulation with muscarine (10-6 M), after 15 min wash out (Wash) and 1 min after stimulation with muscarine in presence of DMS (10-8 M). The bronchi from wild-type (M3R-wt) and M3R-KO mice constricted in response to 10-6 M muscarine. In M3R-wt mice, the constriction was slightly reduced in presence of DMS but abolished in M3R-KO mice. Bar = 200 mum. (B-D) Effect of DHS and DMS on muscarine-mediated reductions in luminal area of murine peripheral bronchi in the absence of the M2R or M3R subtypes. (B-C) Luminal area of peripheral airways from M2R-KO (triangles) and M2R-wt mice (squares)(expressed in % in response to application of 10-6 M muscarine (Mus) alone or after application of muscarine (10-6 M) in combination with DHS (B) or DMS (C) (both 10-8 M). Both DHS and DMS significantly inhibited the muscarine-induced constriction in airways of both M2R-KO and M2R-wt mice. (D, E) Luminal area of peripheral airways (expressed in %) from M3R-KO (triangles) and M3R-wt (squares) mice in response to application of 10-6 M muscarine alone or after application of muscarine (10-6 M) in combination with DHS (D) or DMS (E) (both 10-8 M). Both DHS and DMS significantly inhibited the muscarine-induced constriction in airways of both M3R-KO and M3R-wt mice. Data are given as means +/- S.E.M.
###end p 44
###begin p 45
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>3</italic></sub>
###xml 2 15 2 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R-KO/wt mice </italic>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 340 345 340 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C, D</xref>
###xml 402 405 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 502 503 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 511 516 509 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C, D</xref>
###xml 558 559 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 581 584 579 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 597 600 595 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 606 609 604 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 692 693 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 701 702 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 737 740 733 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 753 755 749 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 761 764 757 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 852 853 848 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 863 864 859 860 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 880 881 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 889 894 885 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C, D</xref>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
M3R-KO/wt mice As in all other experiments, the area of the airway lumen at the beginning of the experiment was defined as 100 %. Application of 10-6 M muscarine constricted peripheral airways in wt-mice by about 66 % (28 slices/25 lungs), whereas in M3R-KO mice the constriction was reduced by about 57 % (29 slices/28 lungs, Tab. 4 Figs. 5C, D, 6). In wt-bronchi, inhibition of SPHK by DHS or DMS (10-8 M each) significantly reduced the initial phase of constriction by about 50 % (58 +/- 12 %, Tab. 4, Figs. 5C, D, 6). Strikingly, treatment of PCLS from M3R-KO mice with DHS (10-8 M) or DMS (10-6 and 10-8 M) almost completely abolished the initial constriction response (94 +/- 4 %, Tab. 4, Figs. 5, 6). Inhibition of SPHK by DHS (10-8 M) or DMS (10-6and 10-8 M) significantly reduced the sustained phase of constriction to a comparable degree in M3R-wt and M3R-KO mice (Tab. 4, Figs. 5C, D, 6).
###end p 45
###begin p 46
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 465 468 464 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 475 478 474 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 546 549 545 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
Effects of DHS and DMS on muscarine-induced reductions in luminal airway area in PCLS from M3 R-KO and their corresponding wild-type mice. The number of experiments (lungs/slices), mean airway diameter in mum, and the muscarine-induced constriction in luminal airway area (expressed in %) determined after 1 min (1) and 15 min (2) after stimulation with muscarine and 1 min (3) and 15 min (4) after stimulation with muscarine in combination with DHS or DMS (both 10-6 M or 10-8 M) are shown. In all experiments, the muscarine concentration was 10-6 M. The initial phase (1 vs 3) and the sustained phase (2 vs 4) of constriction were reduced in presence of DHS or DMS. Data are given as means +/- S.E.M.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
MR signaling pathways play a key role in the regulation of airway resistance which is determined largely by the diameter of smaller, intrapulmonary airways [25]. A better understanding of the different pathways underlying MR activation in the intrapulmonary airways is of considerable clinical relevance. In the present study, we examined the hypothesis that S1P might be involved in the muscarinic control of peripheral airways. To address this question, we used the PCLS model which has been shown to maintain the integrity of all components of the peripheral lung including viable peripheral airways [20].
###end p 48
###begin p 49
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 140 146 <span type="species:ncbi:10090">murine</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 266 272 <span type="species:ncbi:10090">murine</span>
###xml 523 529 <span type="species:ncbi:10090">murine</span>
###xml 725 730 <span type="species:ncbi:10090">mouse</span>
Using double labelling immunohistochemistry we demonstrated for the first time that the SPHK1 protein is highly expressed in the cytosol of murine airway smooth muscle cells with virtually no immunoreactivity in non-smooth muscle cells. On the other hand, human and murine lung tissue showed a high expression and activity of SPHK which was not restricted to smooth muscle alone [13,14]. The virtual restriction of SPHK1-immununoreactivity to smooth muscle could be due to the presence of SPHK isoforms other than SPHK1 in murine lung [14]. At the subcellular level, SPHK1 showed a cytoplasmic localisation but was also found in airway smooth muscle membranes, in agreement with functional and immunoprecipitation studies of mouse lung membranes [14].
###end p 49
###begin p 50
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 329 332 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 376 378 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1076 1078 1076 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1089 1092 1089 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1146 1149 1146 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 1399 1401 1399 1401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+</sup>
###xml 1457 1459 1457 1459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+</sup>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 1309 1313 <span type="species:ncbi:10090">mice</span>
In the present study, the use of membrane-permeable SPHK inhibitors, DHS and DMS [18], convincingly demonstrated that MR-mediated constriction of peripheral airways involves the activation of SPHK. In PCLS preparations from wt-mice, both SPHK inhibitors significantly reduced the fast initial constriction response (induced by 10-6 M muscarine) which is mainly dependent on Ca2+-release from intracellular stores [26]. This effect was observed with the lowest concentrations of the inhibitors but was absent when DHS and DMS were given alone for ten minutes prior to the application of DHS and DMS in combination with muscarine. This inhibition of muscarine induced bronchoconstriction was also absent when we used N-acetylsphingosine (N-AcS), an agent that is structurally related to DHS and DMS but that does not affect SPHK function [5]. These data suggest that DHS and DMS did not exert their inhibitory effects through nonspecific actions. Accordingly, the muscarine-induced initial bronchoconstriction was partly inhibited but persisted in presence of the blockers of Ca2+-influx, La3+ or SKF 96365 [27,28], but was almost abolished when La3+ was applied in combination with DHS or DMS. The sustained phase of muscarine-induced bronchoconstriction was also significantly inhibited by DHS and DMS in FVB mice. Interestingly, the responses that were inhibited by DHS/DMS were SKF96365-but not La3+-sensitive, since DHS/DMS significantly increased the La3+-mediated inhibition of the muscarine-mediated constriction, but had no effect on the SKF96365-mediated inhibition of the constriction.
###end p 50
###begin p 51
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 251 252 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 412 413 412 413 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 504 507 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 674 676 674 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 677 679 677 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 680 681 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
MR-mediated constriction of peripheral airways has been shown to be mediated by a mixture of M2R and M3R subtypes [20]. It is well known that the M3R stimulates IP3-dependent intracellular Ca2+-release ([29,2]. However, like S1P [30], stimulation of M3R can also activate RhoA-dependent signalling pathways leading to increased myofilament sensitivity of smooth muscle [31,32]. On the other hand, activation of M2Rs in airway smooth muscle has been shown to increase the sensitivity of myofilaments to Ca2+ and to inhibit noradrenaline-induced increases in intracellular cAMP [33,34]. In HEK-293 cells, DLS and DMS markedly reduced both M2R-and M3R-mediated increases in [Ca2+]i [5].
###end p 51
###begin p 52
###xml 88 89 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 281 282 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 301 302 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 309 310 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 369 370 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 565 566 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 573 574 573 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 929 930 929 930 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1119 1120 1119 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1213 1214 1213 1214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1252 1253 1252 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 831 836 <span type="species:ncbi:10090">mouse</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
In the present study, we therefore also examined which of these two receptor subtypes (M2R or M3R) is involved in the SPHK1-dependent constriction of peripheral airways. To address this issue, we carried out a series of functional experiments using PCLS preparations from M2R-and M3R-deficient mice (M2R-KO, M3R-KO) and their corresponding wild-type controls (M2R-wt, M3R-wt). To rule out potential differences in SPHK1 expression between wt and KO animals we initially performed a set of quantitative RT-PCR studies. These studies showed that inactivation of the M2R and M3R genes had no significant effect on the relative expression levels of SPHK1 compared to the corresponding wt controls. Moreover, confocal laser scanning microscopic studies showed that the localization and distribution of SPHK1 protein were similar in all mouse strains. In agreement with the results of a previous study [20], the peripheral airways of M3R-KO mice showed an about 50 % reduction in the magnitude of the initial muscarine induced constriction response, as compared to the corresponding response obtained with preparations from M3R-wt mice. We previously demonstrated that the bronchoconstrictor response remaining in the M3R-KO mice is exclusively mediated by M2Rs [20].
###end p 52
###begin p 53
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 307 310 307 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 383 386 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3+ </sup>
###xml 433 436 433 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 753 754 753 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 777 778 777 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 865 866 865 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 889 890 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 949 950 949 950 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1026 1029 1026 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1100 1101 1100 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1355 1357 1355 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1358 1360 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1494 1496 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1497 1499 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1564 1565 1564 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1566 1568 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1628 1629 1628 1629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
Changes in [Ca2+]i are the main trigger in the initiation of MR-mediated bronchoconstriction. The initial phase of constriction of intraparenchymal airways is known to be mediated partly via release of Ca2+ from intracellular stores, as shown by the presence of this phase under blockade of ion influx by La3+ or SKF96365. The considerable reduction of the initial constriction by La3+ or SKF96365 further indicates that influx of Ca2+ is also part of this phase of muscarine-mediated constriction. We defined the bronchoconstriction in response to muscarine as 100 % and analyzed the inhibition under various experimental conditions. Blockade of SPHK1 by either DHS or DMS almost completely abolished the initial phase of constriction in bronchi from M3R-KO mice (Fig. 5 Tab. 2). In contrast, DHS or DMS only partially reduced this early response in bronchi from M2R-KO and wt-mice (Fig. 5). This observation strongly suggests that stimulation of M2Rs mediates activation of SPHK1, which eventually triggers the release of Ca2+ from intracellular stores leading to bronchoconstriction. The role of M2R in airway smooth muscle contraction appears multi-functional in that the receptor can modulate the function of smooth muscle by activation of multiple signalling pathways including tyrosine kinase activation and stimulation/inhibition of ion channels [35,32]. Phosphorylation of myosin light chain and activation of PKC play important roles in the maintenance of smooth muscle contractions [36,37]. Since S1P has been shown to stimulate myosin phosphorylation [8,38], it is likely that this response is also mediated by the M2R subtype.
###end p 53
###begin p 54
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 451 453 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 598 600 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 705 707 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 847 848 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 849 850 848 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
###xml 207 212 <span type="species:ncbi:9606">human</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
###xml 261 267 <span type="species:ncbi:10090">murine</span>
###xml 484 487 <span type="species:ncbi:10116">rat</span>
###xml 653 656 <span type="species:ncbi:9606">man</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
###xml 784 789 <span type="species:ncbi:9606">human</span>
###xml 924 929 <span type="species:ncbi:9606">human</span>
Our findings strongly suggest that SPHK1 activation is part of the signalling response to M2R stimulation in peripheral mouse airways. These airways resemble in their structure and composition of cell types human distal airways [39]. Like human distal airways, murine peripheral airways about 200 mum in diameter that are terminal bronchioles lack submucosal glands, cartilage and contain smooth muscle and Clara cells, in addition to ciliated cells [39]. In studies using monkey and rat peripheral airways, the ACh analogue methacholine (MCh) induced similar responses in large and small mammals [40]. It is therefore likely that the distal airways of man and mice, both of which are also MCh-sensitive [17], share similar MR signalling pathways. In addition, it has been shown that human airway smooth muscle cells constrict in response to S1P [7,8], suggesting that the MR-SPHK1-S1P signalling pathway is also present in human peripheral airways.
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
###xml 428 429 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 172 178 <span type="species:ncbi:10090">murine</span>
In conclusion, in this study we demonstrated the existence of a novel signalling pathway in the regulation of peripheral airways. We found that MR-mediated constriction of murine peripheral airways is mediated, in part, by activation of SPHK. Our data suggest that muscarinic activation of SPHK contributes to the initial and sustained phase of constriction. The SPHK activation in the initial phase is mainly mediated via the M2R subtype. These findings could be of relevance for the development of novel drugs useful for the treatment of chronic obstructive pulmonary disease and asthma. For example, one may speculate that altered S1P signalling may contribute to the hyperreactivity of peripheral airways under pathological conditions.
###end p 56
###begin title 57
List of abbreviations
###end title 57
###begin p 58
ACh acetylcholine
###end p 58
###begin p 59
CT threshold cycle
###end p 59
###begin p 60
MR muscarinic acetylcholine receptor
###end p 60
###begin p 61
wt wild-type control
###end p 61
###begin p 62
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
M2R-KO muscarinic acetylcholine receptor 2-deficient mice
###end p 62
###begin p 63
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
M3R-KO muscarinic acetylcholine receptor 3-deficient mice
###end p 63
###begin p 64
PLCbeta phospholipase C beta
###end p 64
###begin p 65
PCLS Precision cut lung slices
###end p 65
###begin p 66
SKF96365 1-2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl) propoxy]-ethyl-1H-imidazole
###end p 66
###begin p 67
S1P sphingosine 1-phosphate
###end p 67
###begin p 68
SPHK sphingosine kinases
###end p 68
###begin p 69
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
IP3 inositol 1, 4, 5-trisphosphate
###end p 69
###begin p 70
DHS D, L-threo-dihydrosphingosine
###end p 70
###begin p 71
DMS N, N-dimethyl-sphingosine
###end p 71
###begin p 72
NAcS N-acetylsphingosine
###end p 72
###begin p 73
MCh Methacholine
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
###xml 141 145 <span type="species:ncbi:10090">mice</span>
PM, NP, SA, WS, SW and RVH carried out the videomorphometric experiments and performed qRT-PCR and immunohistochemistry. JW developed the KO-mice and participated together with WK and RVH in writing and preparation of the manuscript and in the statistical analysis. YB was involved in the design of the study and the immunohistochemical investigations. The data presented in the manuscript are part of the doctoral thesis of PM, NP, SA, WS.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
We thank Ms K. Michael for skilful technical assistance.
###end p 77
###begin article-title 78
Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling
###end article-title 78
###begin article-title 79
International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors
###end article-title 79
###begin article-title 80
Anticholinergic therapy for airway diseases
###end article-title 80
###begin article-title 81
Sphingosine kinase-mediated Ca2+ signalling by G-protein-coupled receptors
###end article-title 81
###begin article-title 82
Sphingosine kinase-mediated calcium signaling by muscarinic acetylcholine receptors
###end article-title 82
###begin article-title 83
Sphingosine kinase: a mediator of vital cellular functions
###end article-title 83
###begin article-title 84
###xml 34 39 <span type="species:ncbi:9606">human</span>
Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma
###end article-title 84
###begin article-title 85
###xml 50 55 <span type="species:ncbi:9606">human</span>
Sphingosine-1-phosphate stimulates contraction of human airway smooth muscle cells
###end article-title 85
###begin article-title 86
Pulmonary rehabilitation for chronic obstructive pulmonary disease
###end article-title 86
###begin article-title 87
Morphological hysteresis of the small airways
###end article-title 87
###begin article-title 88
Immediate allergic response in small airways
###end article-title 88
###begin article-title 89
###xml 53 59 <span type="species:ncbi:10090">murine</span>
Molecular cloning and functional characterization of murine sphingosine kinase
###end article-title 89
###begin article-title 90
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution
###end article-title 90
###begin article-title 91
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1
###end article-title 91
###begin article-title 92
Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform
###end article-title 92
###begin article-title 93
Ca2+/calmodulin-dependent translocation of sphingosine kinase: role in plasma membrane relocation but not activation
###end article-title 93
###begin article-title 94
###xml 53 59 <span type="species:ncbi:10090">murine</span>
Characterization of airway and vascular responses in murine lungs
###end article-title 94
###begin article-title 95
Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens
###end article-title 95
###begin article-title 96
Muscarinic acetylcholine receptors and airway diseases
###end article-title 96
###begin article-title 97
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice
###end article-title 97
###begin article-title 98
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice
###end article-title 98
###begin article-title 99
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
###end article-title 99
###begin article-title 100
###xml 60 65 <span type="species:ncbi:9606">human</span>
Cell type-specific localization of sphingosine kinase 1a in human tissues
###end article-title 100
###begin article-title 101
Videomicroscopy of methacholine-induced contraction of individual airways in precision-cut lung slices
###end article-title 101
###begin article-title 102
Therapeutic significance of distal airway inflammation in asthma
###end article-title 102
###begin article-title 103
Regulation of second messengers associated with airway smooth muscle contraction and relaxation
###end article-title 103
###begin article-title 104
###xml 37 42 <span type="species:ncbi:9606">human</span>
Receptor-activated calcium influx in human airway smooth muscle cells
###end article-title 104
###begin article-title 105
###xml 70 75 <span type="species:ncbi:9606">human</span>
Endothelin-1 is a potent activator of nonselective cation currents in human bronchial smooth muscle cells
###end article-title 105
###begin article-title 106
Molecular biology of muscarinic acetylcholine receptors
###end article-title 106
###begin article-title 107
Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase
###end article-title 107
###begin article-title 108
Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway
###end article-title 108
###begin article-title 109
Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinary bladder smooth muscle
###end article-title 109
###begin article-title 110
###xml 44 47 <span type="species:ncbi:10116">rat</span>
Characterization of muscarinic receptors in rat bronchial smooth muscle in vitro
###end article-title 110
###begin article-title 111
Muscarinic excitation-contraction coupling mechanisms in tracheal and bronchial smooth muscles
###end article-title 111
###begin article-title 112
###xml 72 77 <span type="species:ncbi:9606">human</span>
Carbachol-induced actin reorganization involves Gi activation of Rho in human airway smooth muscle cells
###end article-title 112
###begin article-title 113
Ca2+ transient, cell volume, and microviscosity of the plasma membrane in smooth muscle
###end article-title 113
###begin article-title 114
Relationship between force and regulatory myosin light chain phosphorylation in airway smooth muscle
###end article-title 114
###begin article-title 115
Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2
###end article-title 115
###begin article-title 116
###xml 74 78 <span type="species:ncbi:10116">rats</span>
Methacholine responsiveness of proximal and distal airways of monkeys and rats using videomicrometry
###end article-title 116

